UBS Oncology Impact Fund L.P.'s Net Worth
$507 Million
Who is UBS Oncology Impact Fund L.P.?
UBS Oncology Impact Fund L.P. has an estimated net worth of $507 Million. This is based on reported shares across multiple companies, which include iTeos Therapeutics, Inc., Cullinan Oncology, Inc., Spring Bank Pharmaceuticals, Inc., Harpoon Therapeutics, Inc., TCR2 THERAPEUTICS INC., SUNESIS PHARMACEUTICALS INC, Werewolf Therapeutics, Inc., and Oncorus, Inc..
SEC CIK
UBS Oncology Impact Fund L.P.'s CIK is 0001691428
Past Insider Trading and Trends
2020 was UBS Oncology Impact Fund L.P.'s most active year for acquiring shares with 24 total transactions. UBS Oncology Impact Fund L.P.'s most active month to acquire stocks was the month of June. 2021 was UBS Oncology Impact Fund L.P.'s most active year for disposing of shares, totalling 145 transactions. UBS Oncology Impact Fund L.P.'s most active month to dispose stocks was the month of August. 2019 saw UBS Oncology Impact Fund L.P. paying a total of $13,506,258.12 for 7,269,851 shares, this is the most they've acquired in one year. In 2022 UBS Oncology Impact Fund L.P. cashed out on 245,469 shares for a total of $10,452,333.95, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
iTeos Therapeutics, Inc. (ITOS) Snapshot price: $10.52
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -5.19% | -245.47K |
$42.58 | -$10,452,333.95 | 4.48M |
Jan 4 - Jan 5
| |||
Form 4
| -1.73% | -83.39K |
$33.73 | -$2,812,427.53 | 4.73M |
Scheduled
|
Dec 3 - Dec 7
| ||
Form 4
| -2.82% | -139.77K |
$34.47 | -$4,817,417.25 | 4.81M |
Scheduled
|
Nov 30 - Dec 2
| ||
Form 4
| -0.77% | -38.57K |
$35.18 | -$1,356,824.98 | 4.95M |
Scheduled
|
Nov 26 - Nov 29
| ||
Form 4
| -0.95% | -145.29K |
$36.85 | -$4,744,666.44 | 15.22M |
Scheduled
|
Nov 17 - Nov 24
| ||
Form 4
| -0.55% | -28.61K |
$27.45 | -$785,384.39 | 5.14M |
Scheduled
|
Oct 15 - Oct 18
| ||
Form 4
| -1.81% | -95.00K |
$27.21 | -$2,584,606.09 | 5.17M |
Scheduled
|
Oct 12 - Oct 14
| ||
Form 4
| -1.63% | -87.01K |
$27.23 | -$2,368,800.16 | 5.26M |
Scheduled
|
Oct 7 - Oct 11
| ||
Form 4
| -0.86% | -46.13K |
$27.05 | -$1,247,589.54 | 5.35M |
Scheduled
|
Oct 1 - Oct 4
| ||
Form 4
| -0.66% | -35.99K |
$27.00 | -$971,730.00 | 5.39M |
Scheduled
|
Sep 28 - Sep 30
| ||
Form 4
| -1.62% | -89.48K |
$27.76 | -$2,484,093.96 | 5.43M |
Scheduled
|
Sep 23 - Sep 27
| ||
Form 4
| -1.02% | -56.78K |
$27.50 | -$1,561,393.60 | 5.52M |
Scheduled
|
Sep 21 - Sep 22
| ||
Form 4
| -2.67% | -152.71K |
$28.38 | -$4,334,451.90 | 5.58M |
Scheduled
|
Sep 16 - Sep 20
| ||
Form 4
| -1.32% | -76.42K |
$27.70 | -$2,116,733.05 | 5.73M |
Scheduled
|
Sep 14 - Sep 15
| ||
Form 4
| -1.63% | -96.46K |
$28.32 | -$2,731,459.64 | 5.81M |
Scheduled
|
Sep 9 - Sep 13
| ||
Form 4
| -1.71% | -102.57K |
$29.03 | -$2,067,786.01 | 5.9M |
Scheduled
|
Sep 7 - Sep 8
| ||
Form 4
| -0.00% | -200.00 |
$29.99 | -$5,998.00 | 6M |
Scheduled
|
Apr 9
| ||
Form 4
| -0.95% | -57.65K |
$30.99 | -$1,300,850.41 | 6M |
Scheduled
|
Apr 7 - Apr 8
| ||
Form 4
| +64.51% | 6.06M |
$19.00 | $6,080,000.00 | 15.46M |
Jul 28
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Werewolf Therapeutics, Inc. (HOWL) Snapshot price: $6.77
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +1,346.05% | 6.21M |
$16.00 |
—
| 6.67M |
May 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Harpoon Therapeutics, Inc. (HARP) Snapshot price: $22.4
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -0.90% | -57.49K |
$20.63 | -$1,186,189.84 | 6.33M |
Scheduled
|
May 28 - Jun 2
| ||
Form 4
| -0.27% | -17.16K |
$20.22 | -$346,937.78 | 6.39M |
Scheduled
|
May 26 - May 27
| ||
Form 4
| -0.25% | -15.91K |
$20.18 | -$321,030.47 | 6.4M |
Scheduled
|
May 21 - May 24
| ||
Form 4
| -0.74% | -47.95K |
$20.49 | -$982,226.63 | 6.42M |
Scheduled
|
May 18 - May 20
| ||
Form 4
| -0.25% | -16.42K |
$20.05 | -$329,313.92 | 6.47M |
Scheduled
|
May 13 - May 17
| ||
Form 4
| -1.04% | -68.26K |
$21.04 | -$1,436,555.54 | 6.48M |
Scheduled
|
May 10 - May 12
| ||
Form 4
| -0.16% | -10.17K |
$22.52 | -$229,107.07 | 6.55M |
Scheduled
|
May 5
| ||
Form 4
| -4.77% | -328.52K |
$22.48 | -$7,386,435.35 | 6.56M |
Scheduled
|
Apr 30 - May 4
| ||
Form 4
| -1.85% | -130.14K |
$21.99 | -$2,861,368.42 | 6.89M |
Scheduled
|
Apr 27 - Apr 29
| ||
Form 4
| -0.13% | -8.97K |
$18.97 | -$170,229.38 | 7.02M |
Scheduled
|
Apr 21
| ||
Form 4
| -0.54% | -38.15K |
$19.04 | -$726,550.34 | 7.03M |
Scheduled
|
Apr 16 - Apr 20
| ||
Form 4
| -0.54% | -38.56K |
$20.16 | -$777,359.18 | 7.07M |
Scheduled
|
Apr 13 - Apr 15
| ||
Form 4
| -0.43% | -30.93K |
$21.90 | -$677,357.16 | 7.11M |
Scheduled
|
Apr 9 - Apr 12
| ||
Form 4
|
∞
| 3.9M |
$11.65 | -$6,258.00 | 3.9M |
Feb 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Spring Bank Pharmaceuticals, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
TCR2 THERAPEUTICS INC. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -3.37M |
—
|
—
|
0
|
Jun 1
| |||
Form 4
|
∞
| 3.37M |
$15.00 |
—
| 3.37M |
Feb 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||